Nadya M. Morrow

Sep 19, 2024 | joe.bioscientifica.com | Neerav Mullur |Arianne Morissette |Nadya M. Morrow |Erin E. Mulvihill

Figure 1 Cardiovascular benefits of GLP-1RA, dual, or triple agonists. (A) Distribution of (in black), or (in blue), and or (in green) mRNA in the heart of humans and mice. (B) Mechanisms of action by which GLP-1RA (black), dual (blue), or triple agonists (green) improve cardiovascular outcomes.

Mar 16, 2023 | jpet.aspetjournals.org | Nadya M. Morrow |Erin E. Mulvihill

Hepatic glucagon and insulin action are central to the systemic regulation of glucose and lipid metabolism. Fasting hepatocytes undergo glycogenolysis and gluconeogenesis in response to a high glucagon-to-insulin ratio. Postprandially, hepatocytes halt glucose production and store excess nutrients as glycogen and lipids in response to a low glucagon-to-insulin ratio (Santoleri and Titchenell, 2019).